ProfileGDS5678 / 1418432_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 88% 88% 88% 87% 88% 88% 88% 88% 88% 88% 88% 87% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6898987
GSM967853U87-EV human glioblastoma xenograft - Control 26.8854988
GSM967854U87-EV human glioblastoma xenograft - Control 36.7907188
GSM967855U87-EV human glioblastoma xenograft - Control 47.0771988
GSM967856U87-EV human glioblastoma xenograft - Control 56.6804987
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5792888
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.5979788
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8748788
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.7937888
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8426688
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.7853988
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9853888
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.7391787
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0424689